Answers are grounded in this paper and cite their sources.
Demonstrates the survival benefits of statin therapy across high-risk cardiovascular conditions, highlighting the urgent need to address suboptimal patient compliance.
Cardiovascular disease (CVD) remains the top cause of global mortality. There is considerable evidence that supports the mortality and morbidity benefit of statin therapy in coronary heart disease (CHD) and stroke, both in primary and secondary prevention settings. Data also exist pointing to the advantage of statin treatment in other high-risk CVD conditions, such as diabetes, CKD, CHF, and PVD. National and international clinical guidelines in the management of these CVD conditions all advocate for the utilization of statin therapy in appropriate patients. However, overall compliance to statin therapy remains suboptimal. Patient-, physician-, and economic-related factors all play a role. These factors need to be considered in devising approaches to enhance adherence to guideline-based therapies. To fully reap the benefits of statin therapy, interventions which improve long-term treatment compliance in real-world settings should be encouraged.
No takes yet. Share an insight, caveat, or question.
Deedwania et al. (2010) conducted a review in High-risk cardiovascular disease (coronary heart disease, stroke, diabetes, chronic kidney disease, chronic heart failure, peripheral vascular disease). Statin therapy was evaluated on Cardiovascular mortality and morbidity. Statin therapy reduces mortality and morbidity in high-risk cardiovascular patients, though overall treatment compliance remains suboptimal due to patient, physician, and economic factors.
Synapse has enriched 10 related papers. Consider them for comparative context: